Atara Biotherapeutics Files 8-K on Leadership and Compensation
Ticker: ATRA · Form: 8-K · Filed: May 15, 2025 · CIK: 1604464
| Field | Detail |
|---|---|
| Company | Atara Biotherapeutics, INC. (ATRA) |
| Form Type | 8-K |
| Filed Date | May 15, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, executive-compensation, corporate-governance
Related Tickers: ATRA
TL;DR
Atara Bio (ATRA) filed an 8-K covering leadership changes and exec comp. Keep an eye on the details.
AI Summary
On May 14, 2025, Atara Biotherapeutics, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The filing also includes information on the company's financial condition and results of operations. Specific details regarding the nature of these changes and their financial implications are expected to be elaborated upon in subsequent filings or disclosures.
Why It Matters
Changes in a company's board and executive compensation can signal shifts in strategic direction or financial health, impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — The filing indicates significant corporate events related to leadership and compensation, which can introduce uncertainty and affect the company's strategic direction and financial outlook.
Key Players & Entities
- Atara Biotherapeutics, Inc. (company) — Registrant
- May 14, 2025 (date) — Date of earliest event reported
FAQ
What specific changes were made to the board of directors?
The filing indicates "Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers" as an item of information, suggesting changes occurred, but the specific names and details of these changes are not provided in this summary section of the 8-K.
What are the details of the compensatory arrangements for certain officers?
The filing lists "Compensatory Arrangements of Certain Officers" as an item of information, indicating that details regarding executive compensation have been disclosed, but the specific terms and amounts are not detailed in this overview.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on May 14, 2025.
What is the principal executive office address for Atara Biotherapeutics, Inc.?
The principal executive office address for Atara Biotherapeutics, Inc. is 1280 Rancho Conejo Blvd, Thousand Oaks, California, 91320.
What is the SIC code for Atara Biotherapeutics, Inc.?
The Standard Industrial Classification (SIC) code for Atara Biotherapeutics, Inc. is 2836, which corresponds to BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 15, 2025 regarding Atara Biotherapeutics, Inc. (ATRA).